A study of oxaliplatin—nucleobase interactions using ion trap electrospray mass spectrometry

Kerr, Samantha L.; Shoeib, Tamer; Sharp, Barry L.
July 2008
Analytical & Bioanalytical Chemistry;Jul2008, Vol. 391 Issue 6, p2339
Academic Journal
Oxaliplatin is an important anti-cancer drug that has been approved for the treatment of colorectal cancer. It is known that oxaliplatin, like other Pt-based drugs, interacts with DNA to form cytotoxic Pt-DNA adducts that disrupt important biological processes such as DNA replication and protein synthesis. Linear ion trap electrospray ionisation mass spectrometry (ESI-MS) was employed to study the interaction of oxaliplatin with DNA nucleobases. It was shown that oxaliplatin formed adducts with all four DNA nucleobases when present individually and in combination in solution. Multiple-stage tandem mass spectrometry (MSn) enabled the fragmentation pathways of each adduct to be established. In addition, proposed structures for each product ion were obtained from the MS data. When all four bases were present together with the drug at near-equal molar concentrations, adducts containing predominantly adenine and guanine were formed, confirming that the drug preferentially binds to these nucleobases. A large molar excess of drug was required to ensure the formation of cytosine and thymine adducts in the presence of adenine and guanine. Even with a large excess of oxaliplatin, only mono-adducts of these nucleobases were observed when all four nucleobases were present. [Figure not available: see fulltext.]


Related Articles

  • Mebendazole/oxaliplatin.  // Reactions Weekly;Apr2014, Vol. 1497 Issue 1, p26 

    The article presents a case study of a 74-year-old metastatic colon cancer male patient with neuropathy which developed while being treated with oxaliplatin and with elevated liver enzymes that developed while receiving mebendazole.

  • Overexpression of Cohesion Establishment Factor DSCC1 through E2F in Colorectal Cancer. Yamaguchi, Kiyoshi; Yamaguchi, Rui; Takahashi, Norihiko; Ikenoue, Tsuneo; Fujii, Tomoaki; Shinozaki, Masaru; Tsurita, Giichiro; Hata, Keisuke; Niida, Atsushi; Imoto, Seiya; Miyano, Satoru; Nakamura, Yusuke; Furukawa, Yoichi // PLoS ONE;Jan2014, Vol. 9 Issue 1, p1 

    Ctf18-replication factor C complex including Dscc1 (DNA replication and sister chromatid cohesion 1) is implicated in sister chromatid cohesion, DNA replication, and genome stability in S. cerevisiae and C. elegans. We previously performed gene expression profiling in primary colorectal cancer...

  • Oxaliplatin.  // Reactions Weekly;6/14/2008, Issue 1206, p23 

    The article describes the case of a 59-year-old woman who developed hypokalaemia and hypocalcaemia and fell into a reversible coma, while undergoing treatment with oxaliplatin for colorectal cancer. 15 minutes after the oxaliplatin infusion, the patient experienced diplopia, dysarthria and...

  • Oxaliplatin.  // Reactions Weekly;1/11/2014, Issue 1483, p76 

    The article presents case studies of three patients, aged 52 to 64 years, with anaphylaxis during use of oxaliplatin chemotherapy for their colorectal cancer.

  • Toxicity associated with combination oxaliplatin plus fluoropyrimidine with or without cetuximab in the MRC COIN trial experience. Adams, R. A.; Meade, A. M.; Madi, A.; Fisher, D.; Kay, E.; Kenny, S.; Kaplan, R. S.; Maughan, T. S. // British Journal of Cancer;1/27/2009, Vol. 100 Issue 2, p251 

    We present the preliminary toxicity data from the MRC COIN trial, a phase III randomised controlled trial of first-line therapy in advanced colorectal cancer, with particular reference to the addition of cetuximab to an oxaliplatin-fluoropyrimidine combination. A total of 804 patients were...

  • Popular colorectal cancer drug may cause permanent nerve damage.  // Biomedical Market Newsletter;9/30/2011, Vol. 21, p149 

    The article reports on the potential of oxaliplatin, a platinum-based anticancer drug used for the treatment of colorectal cancer, to cause permanent nerve damage that could worsen even after treatment terminates.

  • In Vitro Investigation of DNA Damage Induced by the DNA Cross-Linking Agents Oxaliplatin and Satraplatin in Lymphocytes of Colorectal Cancer Patients. Alotaibi, Amal; Baumgartner, Adolf; Najafzadeh, Mojgan; Cemeli, Eduardo; Anderson, Diana // Journal of Cancer Therapy;Feb2012, Vol. 3 Issue 1, p78 

    Exposure to toxic chemicals, especially chemotherapeutic drugs, may induce several DNA lesions, including DNA interstrand crosslinks. These crosslinks are considered toxic lesions to the dividing cells since they can induce mutations, chromosomal rearrangements, and cell death. Many DNA...

  • Genetic variants in DNA repair genes as potential predictive markers for oxaliplatin chemotherapy in colorectal cancer. Kap, E J; Seibold, P; Richter, S; Scherer, D; Habermann, N; Balavarca, Y; Jansen, L; Becker, N; Pfütze, K; Popanda, O; Hoffmeister, M; Ulrich, A; Benner, A; Ulrich, C M; Burwinkel, B; Brenner, H; Chang-Claude, J // Pharmacogenomics Journal;Dec2015, Vol. 15 Issue 6, p505 

    Oxaliplatin-based chemotherapy exerts its effects through generating DNA damage. Hence, genetic variants in DNA repair pathways could modulate treatment response. We used a prospective cohort of 623 colorectal cancer patients with stage II-IV disease treated with adjuvant/palliative chemotherapy...

  • Oxaliplatin: pre-clinical perspectives on the mechanisms of action,response and resistance. Seetharam, R. N.; Sood, A.; Goel, S. // Ecancermedicalscience;2009, Vol. 3, p1 

    Oxaliplatin is a third-generation platinum compound that has shown a wide range of anti-tumour activity in metastatic cancer and in multiple cell lines. It contains a diaminocyclohexane carrier ligand and is one of the least toxic platinum agents. In the past decade, the use of oxaliplatin for...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics